- Supported exchanges /
- F /
- 2QK.F
SCHOLAR ROCK HLDG DL-001 (2QK F) stock market data APIs
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
SCHOLAR ROCK HLDG DL-001 Financial Data Overview
| 28 | |
| 27.6 | |
| - | |
| 28 | |
| 27.6 | |
| 6.15-31.8 | |
| 2 492 M | |
| 90 298 K | |
| 0 | |
| -0.84 | |
| 0.824 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
SCHOLAR ROCK HLDG DL-001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -207 144 992
- Earnings Per Share -2.06
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get SCHOLAR ROCK HLDG DL-001 Earnings via APIs
- Latest Release 2021-06-30
- EPS/Forecast -0.78
Get SCHOLAR ROCK HLDG DL-001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
